Document Type
Research Article
Abstract
The latest anti-diabetic medication sodium-glucose co-transporter inhibitor along with the lowering of blood glucose has a cardioprotective and reno-protective effect, it has the ability to reduce the development of heart failure and decrease hospitalization in heart failure subjects with and without diabetes. This study was conducted to evaluate the effect of sodium-glucose co-transporter inhibitor dapagliflozin alone and in combination with eplerenone on the aldosterone hormone in the treatment of rats with experimentally induced heart failure
Keywords
dapagliflozin, eplerenone, heart failure, aldosterone, neurohormonal change.
How to Cite This Article
Jawhar, Skala Mamand and Mustafa, Zana Ahmed
(2023)
"The The Impact of Dapagliflozin on Aldosterone Hormone in Rats with Heart Failure,"
Polytechnic Journal: Vol. 12:
Iss.
2, Article 7.
DOI: https://doi.org/10.25156/ptj.v12n2y2022.pp53-60
References
Bahriz, A. et al. (2021) ‘Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction Induced Experimentally in Diabetic Rats’, Benha Medical Journal, 38(Academic issue), pp. 147–165.
Berg, D. D. et al. (2021) ‘Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial’, Circulation.
Chin, K. L. et al. (2019) ‘Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate’, Clinical Research in Cardiology, 108(7), pp. 806–814.
Choi, H.-M., Park, M.-S. and Youn, J.-C. (2019) ‘Update on heart failure management and future directions’, The Korean journal of internal medicine. 2018/12/28, 34(1), pp. 11–43. doi: 10.3904/kjim.2018.428.
Das, B. B. and Solinger, R. (2009) ‘Role of natriuretic peptide family in cardiovascular medicine’, Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents), 7(1), pp. 29–42.
Dizaye, K. and Ali, R. H. (2019) ‘Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure’, BMC Pharmacology and Toxicology, 20(1), p. 23. doi: 10.1186/s40360- 019-0304-z.
Dizaye, K. and Mustafa, Z. A. (2019) ‘The effect of eplerenone on the renin-angiotensin-aldosterone system of rats with thyroid dysfunction’, Journal of Pharmacy and Pharmacology, 71(12), pp. 1800–1808.
Ghanim, H. et al. (2021) ‘Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors’, Diabetes, Obesity and Metabolism, 23(7), pp. 1614–1623.
Hartupee, J. and Mann, D. L. (2017) ‘Neurohormonal activation in heart failure with reduced ejection fraction’, Nature reviews. Cardiology. 2016/10/06, 14(1), pp. 30–38. doi: 10.1038/nrcardio.2016.163.
Inamdar, A. A. and Inamdar, A. C. (2016) ‘Heart Failure: Diagnosis, Management and Utilization’, Journal of clinical medicine, 5(7), p. 62. doi: 10.3390/jcm5070062.
Isshiki, M. et al. (2020) ‘Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration’, Endocrine Journal, pp. EJ20-0222.
Konecny, F. (2021) ‘Rodent General Anesthesia Suitable for Measurement of Experimental Invasive Hemodynamics’, European Journal of Biology and Biotechnology, 2(4), pp. 33–43.
Lilly, L. S. (2012) Pathophysiology of heart disease: a collaborative project of medical students and faculty. Lippincott Williams & Wilkins
Lobo Filho, H. G. et al. (2011) ‘Experimental model of myocardial infarction induced by isoproterenol in rats’, Brazilian Journal of Cardiovascular Surgery, 26, pp. 469–476.
Lytvyn, Y. et al. (2017) ‘Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials’, Circulation, 136(17), pp. 1643–1658.
Narasimhan, B. et al. (2021) ‘Pharmacotherapeutic principles of fluid management in heart failure’, Expert Opinion on Pharmacotherapy, 22(5), pp. 595–610
Nichtova, Z. et al. (2012) ‘Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol’, Gen Physiol Biophys, 31(2), pp. 141–151.
Rajasekeran, H., Lytvyn, Y. and Cherney, D. Z. I. (2016) ‘Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis’, Kidney International, 89(3), pp. 524–526. doi: 10.1016/J.KINT.2015.12.038.
Ramani, G. V, Uber, P. A. and Mehra, M. R. (2010) ‘Chronic heart failure: contemporary diagnosis and management’, Mayo Clinic proceedings, 85(2), pp. 180–195. doi: 10.4065/mcp.2009.0494.
Rossignol, P. et al. (2011) ‘Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects: insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival St’, Journal of the American College of Cardiology, 58(19), pp. 1958–1966.
Sano, M. (2018) ‘A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity’, Journal of Cardiology, 71(5), pp. 471–476.
Sawamura, T. et al. (2020) ‘Effect of sodium–glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study’, BMC endocrine disorders, 20(1), pp. 1–8.
Singh, V. et al. (2010) ‘Cardiac biomarkers – the old and the new: a review’, Coronary Artery Disease, 21(4). Available at: https://journals.lww.com/coronary-artery/Fulltext/2010/06000/Cardiac_biomarkers___the_old_and_the_new__a_review.7.aspx.
Tentolouris, A. et al. (2019) ‘SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects’, International journal of environmental research and public health, 16(16), p. 2965. doi: 10.3390/ijerph16162965.
Publication Date
2-1-2023
Follow us: